Back in November 2020, Cassava priced its public offering at $8 per share. Proceeds of $75 million were meant to support the Phase 3 study. Since then, SAVA stock has traded as high as $146, without a ...

Last month we discussed that Cassava Sciences stock (NASDAQ: SAVA), based on historical performance, is likely to see lower levels after it plunged 24% in a week following a citizen petition filed to ...

Good biotech companies develop and commercialize medicines that are safe and effective. Good medicines tend to be the result of good science. And while defining good science is beyond the scope of ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Facing charges from the Securities and Exchange Commission for misleading claims ...

The stock's been a wild ride for investors all year, and it's dropped more than 50% in two days. What's going on, and why am I bullish? Editor's Note: This article was updated on Aug. 31 to reflect ...

Shares of clinical-stage biotech Cassava Sciences (NASDAQ: SAVA) soared in 2021 for a couple of reasons. First, the company produced strong results in clinical studies for its potential therapy for ...

Cassava Sciences (SAVA) announced the appointment of Freda Nassif as Chief Commercial Officer, effective today. “I am thrilled to expand Cassava’s leadership team and welcome Freda Nassif as Chief ...

Shares of Cassava Sciences (NASDAQ: SAVA) were skyrocketing 29.6% higher as of 10:53 a.m. ET on Monday. The big gain came after executive chairman Rick Barry released an open letter to shareholders, ...

The stock price of Cassava Sciences (NASDAQ: SAVA) plunged 23% yesterday after a report that the U.S. SEC is investigating the company over allegations of data manipulation for its experimental ...

The biotech company behind an experimental Alzheimer's disease treatment that it thinks could not only stop the progression of the disease but also actually improve patients' symptoms, is under ...